(INNF)
SAMALIZUMAB(INNS)
SAMALIZUMAB(INND)
SAMALIZUMAB(INNC)
IMMUNOGLOBULIN G2/4-KAPPA, ANTI-[HOMO SAPIENS CD200 (OX-2)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA2 HEAVY CHAIN (1-442) [HUMANIZED VH (HOMO SAPIENS IGHV1-69*01 (73.50%) -(IGHD)-IGHJ4*01 L123>T, V124>L) [8.8.10] (1-117) -HOMO SAPIENS IGHG2*01 CH1-HINGE-CH2 1.6-1.1 (118- 232)- IGHG4*01 CH2 1-125, CH3 1-129 K130>DEL (233-442)], (131- 214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1-33*01 (81.10%) -IGKJ2*01 Q120>G) [6.3.9] (1'-107') -HOMO SAPIENS IGKC*01 (108'-214')]; (219-219":220- 220":223-223":226-226")-TETRAKISDISULFIDE DIMER, RECOMMENDED INN: LIST 65(WHO)
SAMALIZUMABUM(INN)